Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...

Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

Volker Herrmann, M.D., has also stepped away from the helm, with Sonata chairman David Khougazian taking the wheel as acting ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a ...

After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...

A study found that undergoing a cardiac ablation procedure first—before taking any antiarrhythmic therapies—may be the better ...

Alzheimer’s and Huntington’s patients do have different symptoms and disease biology, but that made no difference to the ...